Aller au contenu principal
2026 article

Parthenolide: Unlocking the Multitarget Molecular Regulatory Network of Neurological Diseases

0Citations signalées, ce qui n’est pas une note de qualité
1Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

INTRODUCTION: Neurological diseases with a complex etiology and diagnostic complexities are one of the major causes of disability and death globally. In previous preclinical studies, it has been shown that parthenolide (PTL) can provide significant neuroprotective potential. The review synthesizes the mechanistic data on PTL that explains the routes to therapy and creates a strong theoretical framework for future research and drug development. METHODS: This review has done a literature search in databases of PubMed, Web of Science, China Science Periodical Database, and China National Knowledge Infrastructure for preclinical studies on PTL. The search terms used were "Parthenolide" and "Nervous System Diseases" as well as specific names of the diseases. We reviewed the mechanistic understanding on PTL of the available literature. RESULTS: PTL inhibits the pathogenesis and development of neurological disease via a wide variety of mechanisms, such as an anti-inflammatory effect, an anti-oxidative stress effect, a reduction of neuronal apoptosis, and the relief of neuropathic pain. Since it addresses more than one pathway in the multifactorial pathological network of neurological illnesses, PTL may have synergistic or additive therapeutic benefits. DISCUSSION: Multi-target therapeutic effects of PTL are effective in combating the interrelated pathological conditions of neurological disorders, whereas derivatives developed according to the structure-activity relationship (SAR) of PTL have additional potential to be clinically translated. Nevertheless, the existing data come mostly in the form of preclinical models, and their translation into clinical practice remains to be confirmed. CONCLUSION: PTL is a therapeutic agent with great promise in treating neurological disorders. Nevertheless, its potential as a translational drug also requires additional study and confirmation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Parthenolide: Unlocking the Multitarget Molecular Regulatory Network of Neurological Diseases
Date Crossref
07/05/2026
Éditeur
Bentham Science Publishers Ltd.
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

  • Shandong University of Traditional Chinese Medicine pays non établi dans la notice
    Université ou école supérieure
  • Department of Acupuncture and Massage College pays non établi dans la notice
    Université ou école supérieure
  • ShandongUniversity of Traditional Chinese Medicine Key Laboratory of Traditional Chinese Medicine Classical Theory pays non établi dans la notice
    Université ou école supérieure

Shandong University of Traditional Chinese Medicine, Department of Acupuncture and Massage College et Key Laboratory of Traditional Chinese Medicine Classical Theory — ShandongUniversity of Traditional Chinese Medicine.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Sesquiterpenes and Asteraceae StudiesProtease and Inhibitor MechanismsBone Metabolism and Diseases

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.